Bonnet Mehdi, Eckert Catherine, Tournebize Régis
Département de Bactériologie, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France.
Centre d'Immunologie et des Maladies Infectieuses, INSERM, U1135, Sorbonne Université, Paris, France.
Front Microbiol. 2023 Nov 23;14:1266416. doi: 10.3389/fmicb.2023.1266416. eCollection 2023.
Antimicrobial resistance is a major threat to human and animal health and accounted for up to 4.5 million deaths worldwide in 2019. Asymptomatic colonization of the digestive tract by multidrug resistant (multi-resistant) bacteria such as extended-spectrum beta-lactamase-, or carbapenemase- producing is (i) a risk factor for infection by these multi-resistant bacteria, (ii) a risk factor of dissemination of these multi-resistant bacteria among patients and in the community, and (iii) allows the exchange of resistance genes between bacteria. Hence, decolonization or reduction of the gastrointestinal tract colonization of these multi-resistant bacteria needs to be urgently explored. Developing new non-antibiotic strategies to limit or eradicate multi-resistant bacteria carriage without globally disrupting the microbiota is considered a priority to fight against antibiotic resistance. Probiotics or Fecal Microbiota Transplantation are alternative strategies to antibiotics that have been considered to decolonize intestinal tract from MDR bacteria but there is currently no evidence demonstrating their efficacy. Lytic bacteriophages are viruses that kill bacteria and therefore could be considered as a promising strategy to combat antibiotic resistance. Successful decolonization by bacteriophages has already been observed clinically. Here, we discuss the current alternative strategies considered to decolonize the digestive tract of multidrug resistant bacteria, briefly describing probiotics and fecal microbiota transplantation approaches, and then detail the and studies using bacteriophages, while discussing their limits regarding the animal models used, the characteristics of phages used and their activity in regards of the gut anatomy.
抗菌药物耐药性是对人类和动物健康的重大威胁,2019年在全球导致多达450万人死亡。产超广谱β-内酰胺酶或碳青霉烯酶等多重耐药菌在消化道的无症状定植:(i)是这些多重耐药菌感染的危险因素;(ii)是这些多重耐药菌在患者之间和社区传播的危险因素;(iii)会使细菌之间发生耐药基因交换。因此,迫切需要探索对这些多重耐药菌进行去定植或减少其在胃肠道定植的方法。开发新的非抗生素策略以限制或根除多重耐药菌的携带,同时又不全面破坏微生物群,被认为是对抗抗生素耐药性的优先事项。益生菌或粪便微生物群移植是抗生素的替代策略,曾被认为可使肠道中的多重耐药菌去定植,但目前尚无证据证明其有效性。裂解性噬菌体是能杀死细菌的病毒,因此可被视为对抗抗生素耐药性的一种有前景的策略。临床上已观察到噬菌体成功实现去定植的情况。在此,我们讨论目前被认为可使多重耐药菌在消化道去定植的替代策略,简要描述益生菌和粪便微生物群移植方法,然后详细介绍使用噬菌体的研究,并讨论其在所用动物模型方面、所用噬菌体特性及其在肠道解剖结构方面的活性的局限性。